MINNEAPOLIS, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on...
Q3W schedule of CRB-701 (SYS6002) demonstrates a 43% ORR and 71% DCR at predicted therapeutically relevant dosesAll assessable nectin-4 positive...
WALTHAM, Mass., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the Committee for Medicinal...
ZUG, Switzerland, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor...
January 26, 2024 – Company announcement no. 1 Please see attachment. Contact information Investor RelationsDisa Tuominen+45 6038 5826dkditu@chr-hansen.com Press RelationsSanne...
Please read the full announcement in PDF Attachment 2024_01_All_Regulatory_Approvals_Obtained
ORION CORPORATION PRESS RELEASE 26 JANUARY 2024 at 09.00 EET Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024Orion presented yesterday...
NEWTOWN SQUARE, Pa., Jan. 25, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to...
SAN MATEO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing...
TORONTO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group"), a clinical-stage life science biotechnology company pioneering the...
TORONTO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (“Psyence Biomed”) is excited to announce the completion of its...
Clinical experience with investigational ARC-EX® Therapy showcased on the main stage and in clinical abstracts during the 2024 NANS Annual...
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today...
SAN RAMON, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO) today announced it will report first quarter 2024...
Safety and initial efficacy data from Stage 1 expected in the first half of 2024 Dose selection and initiation of...
MINNEAPOLIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and...
Renalys expected to initiate registrational study in the second quarter of 2024 to support potential approval of sparsentan for IgA...
FORT LAUDERDALE, FLA, Jan. 25, 2024 (GLOBE NEWSWIRE) -- PreVu Software, a pioneer in dental technology solutions, proudly announces the...
Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE) Approval...
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared...